GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma board approves merger of Auroactive Pharma with Apitoria Pharma

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 04 Nov 2026, 08:28 PM IST  ·  BSE ID: 5eaae42e-2a48-4508-8804-ba6a548be7d9
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma is merging two of its fully-owned drug ingredient making companies, one with INR 64,430.8 million turnover.
🤖 AI Summary
  • Aurobindo Pharma's board approved the merger of wholly owned subsidiaries Auroactive Pharma and Apitoria Pharma.
  • Auroactive Pharma recorded a turnover of INR 701.3 million for the financial year ended March 31, 2026.
  • Apitoria Pharma reported a turnover of INR 64,430.8 million for the financial year ended March 31, 2026.
  • Both merged entities operate in the active pharmaceutical ingredients (API) manufacturing business.
  • The merger intends to consolidate API businesses, enhance operational efficiency, and simplify corporate structure.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Auroactive Pharma Turnover FY26
701.3 INR million
Apitoria Pharma Turnover FY26
64,430.8 INR million
Auroactive Pharma Equity Share Capital
2,470,000,000 INR
🏢 How This Affects the Company
📈
Business Impact
The merger consolidates Aurobindo Pharma's active pharmaceutical ingredient (API) businesses under a single entity, aiming for greater focus and unified strategy in this segment.
💰
Financial Impact
The merger is between wholly owned subsidiaries and does not directly alter Aurobindo Pharma's consolidated financial statements or shareholding pattern.
⚙️
Operational Impact
This consolidation is intended to improve operational efficiency and optimize capacity utilization of the Auroactive Pharma facility by integrating it into Apitoria Pharma.
⚠️
Risk Impact
The simplification of the group's corporate structure by merging these two entities could reduce administrative complexities and associated compliance risks.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders of Aurobindo Pharma Ltd as the company is not a party to the Scheme of Amalgamation.
👤
Who Is Affected
Shareholders of Aurobindo Pharma Ltd are not directly affected by this intra-group merger as the shareholding pattern of the listed entity remains unchanged.
🔍
Management Signal
This decision indicates management's intent to streamline corporate structure and consolidate core business segments for improved operational and strategic coherence.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
NCLT Hyderabad approval status for the Scheme of Amalgamation filing.
Updates on the effective date of the merger completion.
Any further disclosures regarding integration plans of the API businesses.
LOW RISK This is an intra-group merger between wholly owned subsidiaries and does not directly expose the parent company to new external risks.
💡 Investor Takeaway
Aurobindo Pharma's board approved the merger of Auroactive Pharma (FY26 turnover: INR 701.3 million) with Apitoria Pharma (FY26 turnover: INR 64,430.8 million). This aims to consolidate API businesses and improve operational efficiency.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidation of API businesses under a single entity, Apitoria Pharma, aims to enhance strategic alignment and resource allocation.
  • The merger is structured to improve operational efficiency and optimize capacity utilization for the Auroactive facility.
📅 Company Track Record
Aurobindo Pharma has shown a trend towards corporate restructuring and consolidation. In August 2026, it initiated a merger of three injectable pharma subsidiaries. In July 2026, it completed the transfer of its domestic branded generics business to Auropharm and also acquired majority ownership in A1 Biochem Labs. This latest merger aligns with prior efforts to streamline operations.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
Which Aurobindo Pharma subsidiaries are merging?
Aurobindo Pharma Private Limited (Transferor Company) is merging with Apitoria Pharma Private Limited (Transferee Company). Both are wholly owned subsidiaries.
What were the turnovers of the merging companies in FY26?
Auroactive Pharma's turnover for FY26 was INR 701.3 million, and Apitoria Pharma's turnover for FY26 was INR 64,430.8 million.
What is the primary business area of Auroactive Pharma and Apitoria Pharma?
Both Auroactive Pharma and Apitoria Pharma are engaged in the manufacture of active pharmaceutical ingredients (APIs).
What is the exchange ratio for shares in the merger?
97 equity shares of Apitoria Pharma Private Limited (face value INR 10 each) will be issued for every 10,000 equity shares of Auroactive Pharma Private Limited (face value INR 10 each), totaling 23,95,900 Apitoria shares.
Will Aurobindo Pharma's shareholding pattern change due to this merger?
No, the shareholding pattern of Aurobindo Pharma Limited will remain unchanged as the company is not a party to this Scheme of Amalgamation between its wholly owned subsidiaries.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.